<DOC>
	<DOCNO>NCT00983190</DOCNO>
	<brief_summary>Study Purpose The purpose BeneMACS Long-Term LVAD Study demonstrate survival non transplant patient implanted HeartMate II LVAD destination therapy Belgium Netherlands equivalent well publish result scientific literature approve device . Implants perform follow HeartMate II guideline . Characterization Patient Population The HeartMate II implant destination therapy patient candidate cardiac transplantation . Study Design The study prospective , non-randomized , non-blinded multi-center study historical control . The study consist assignment eligible patient treatment LVAD . The first 10 patient device implant enrolled study . Study End point Patients enrol study follow end point define death , 2-year support HeartMate II , device removal , transplantation , recovery . Data Collection Follow-up All data enter INTERMACS® web-based data entry system . All data BeneMACs study hold separately main INTERMACS database , use purpose BeneMACs study . Investigator sit Cliniques Universitaires St. Luc , Avenue Hippocrates 10 , 1200 Brussels , Belgium Leuven Gasthuisberg University Hospital , Herestraat 49 , 3000 Leuven , Belgium</brief_summary>
	<brief_title>BeneMACS Study : HeartMate 2 ( HM2 ) Left Ventricular Assist Device ( LVAD ) Survival Non Transplant Patients Equal/Better Than Results Medical Literature</brief_title>
	<detailed_description>1 . STUDY OBJECTIVE The purpose BeneMACs Long-Term LVAD Study demonstrate survival non transplant patient implanted HeartMate II LVAD destination therapy Belgium Netherlands equivalent well publish result scientific literature approve device . ( see section 4.6.4 ) Implants perform follow HeartMate II guideline . 2 . STUDY ENTRY CRITERIA - PATIENT SELECTION 2.1 Characterization Patient Population The HeartMate II implant destination therapy patient candidate cardiac transplantation . 3 . METHODS 3.1 Study Design The study prospective , non-randomized , non-blinded multi-center study historical control . The study consist assignment eligible patient treatment LVAD . The first 10 patient device implant enrolled study . 3.2 Study End point Patients enrol study follow end point define death , 2-year support HeartMate II , device removal , transplantation , recovery . 3.3 Number Clinical Sites Patients The study conduct three ( 3 ) clinical site . A total 10 patient ( 3-4 patient per site ) enrol implant HM II . 3.4 Data Collection Follow-up : All data enter INTERMACS® web-based data entry system . Complete documentation Site User 's Guide contain data entry website ( www.intermacs.org ) . INTERMACS ( Interagency Registry Mechanical Assisted Circulatory Support ) form partnership National Heart Lung , Blood Institute ( NHLBI ) , FDA , Centers Medicare Medicaid Services ( CMS ) , participate hospital industry ( reference 7.2 ) . It main MCS registry United States . In addition primary purpose , validate database use INTERMACS also make available service study mechanical circulatory support device BeneMACs study . All data BeneMACs study hold separately main INTERMACS database , use purpose BeneMACs study .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Patient legal representative sign informed consent . &gt; 18 year age . BSA &gt; 1.3m2 . Patients advanced heart failure symptom ( Class IIIB IV ) : ( patient must meet one follow ) On optimal medical management , include dietary salt restriction , diuretic , betablockers , spironolactone ACE inhibitor , least 45 last 60 day fail respond ; In Class III Class IV heart failure least 14 day , dependent intra aortic balloon pump ( IABP ) 5 day and/or inotropes least 10 day ; Treated ACE inhibitor betablockers least 30 day find intolerant . Female patient childbearing potential must agree use adequate contraceptive precaution ( defined oral contraceptive , intrauterine device , surgical contraceptive combination condom spermicide ) duration study . Ineligible cardiac transplant . VO2max &lt; 14 ml/kg/min &lt; 50 % predict VO2max attainment anaerobic threshold ( AT ) , contraindicate due IV inotropes , angina physical disability . LVEF &lt; 25 % . Etiology heart failure due associate uncorrected thyroid disease , obstructive cardiomyopathy , pericardial disease , amyloidosis , active myocarditis restrictive cardiomyopathy . Technical obstacle , pose inordinately high surgical risk , judgment investigator . Body Mass Index ( BMI ) &gt; 40 kg/m2 . Positive pregnancy test female childbearing age . Presence mechanical aortic valve convert bioprosthesis time LVAD implant . History cardiac transplant cardiomyoplasty . Platelet count &lt; 50,000 . Evidence untreated aortic aneurysm &gt; 5cm . Psychiatric disease , irreversible cognitive dysfunction psychosocial issue likely impair compliance study protocol LVAD management . Presence active , uncontrolled infection . Intolerance anticoagulant antiplatelet therapy peri/post operative therapy investigator require base upon patient 's health status . INR &gt; 2.5 , due anticoagulant therapy , Plavix administration within 5 day . Evidence intrinsic hepatic disease define liver enzyme value ( AST ALT total bilirubin ) &gt; 5 time upper limit normal , biopsy proven liver cirrhosis . History severe COPD severe restrictive lung disease . Fixed pulmonary hypertension PVR &gt; 8 Wood unit unresponsive pharmacological intervention . History stroke within 90 day prior enrollment , history cerebral vascular disease significant ( &gt; 80 % ) extra cranial stenosis . Serum creatinine &gt; 3.5 mg/dl need chronic renal replacement therapy ( e.g . chronic dialysis ) . Significant peripheral vascular disease accompany rest pain extremity ulceration . The patient moderate severe aortic insufficiency without plan correction pump implantation surgery . Participation clinical investigation likely confound study result affect study outcome . Any condition , heart failure , likely limit survival le 3 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>HeartMate II</keyword>
	<keyword>BeneMACS</keyword>
	<keyword>LVAD</keyword>
	<keyword>Thoratec Corporation</keyword>
</DOC>